About belite bio inc. - BLTE
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
BLTE At a Glance
Belite Bio, Inc.
12750 High Bluff Drive
San Diego, California 92130
| Phone | 1-858-246-6240 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -36,144,000.00 | |
| Sector | Health Technology | Employees | 25 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BLTE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 13.772 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -45.069 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
BLTE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,445,760.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BLTE Liquidity
| Current Ratio | 24.31 |
| Quick Ratio | 24.31 |
| Cash Ratio | 23.992 |
BLTE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -29.293 |
| Return on Equity | -30.598 |
| Return on Total Capital | -24.696 |
| Return on Invested Capital | -30.49 |
BLTE Capital Structure
| Total Debt to Total Equity | 0.368 |
| Total Debt to Total Capital | 0.367 |
| Total Debt to Total Assets | 0.353 |
| Long-Term Debt to Equity | 0.179 |
| Long-Term Debt to Total Capital | 0.178 |